Biomind Labs Return on Equity

Biomind Labs (BMNDF) currently reports a ROE of 76.75%. That is above the Healthcare sector average of -75.84%. Use the charts on this page to explore Biomind Labs's ROE history and peer comparisons.

Biomind Labs's ROE of 76.75% is higher than the Healthcare sector average of -75.84%. That is roughly 201.2% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biomind Labs's current 76.75% should be judged against Healthcare norms (sector average: -75.84%) and against BMNDF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of 76.75%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.84%. From there, open related valuation or income-statement pages for Biomind Labs, and consider following BMNDF for alerts when major investors trade the stock.

Biomind Labs is classified in the Healthcare sector. On ROE, it currently shows 76.75% versus a sector average near -75.84%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BMNDF with unrelated industries.